We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

High-sensitivity C-reactive Protein and United Kingdom Prospective Diabetes Study (UKPDS) Risk Score in Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01099865
Recruitment Status : Completed
First Posted : April 8, 2010
Last Update Posted : April 8, 2010
Information provided by:
Korea University

Brief Summary:
The UKPDS risk score is recommended to assess global risk for future coronary heart disease (CHD) events in primary prevention. Recently, high-sensitivity C-reactive protein (hsCRP) has emerged as a strong independent risk factor for CHD. 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) is a promising imaging technique for the evaluation of vascular inflammation that reflects vulnerable atherosclerotic plaque.

Condition or disease
Atherosclerosis Type 2 Diabetes

Layout table for study information
Study Type : Observational
Actual Enrollment : 56 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: High-sensitivity C-reactive Protein and UKPDS Risk Score in Type 2 Diabetes: Nalysis With 18F-Fluorodeoxyglucose Positron Emission Tomography
Study Start Date : December 2009
Actual Primary Completion Date : April 2010
Actual Study Completion Date : April 2010

Resource links provided by the National Library of Medicine

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   16 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
type 2 diabetes

Inclusion Criteria:

  • Type 2 diabetes

Exclusion Criteria:

  • Myocardial infarction, unstable angina, stroke, peripheral artery disease, or cardiovascular revascularization
  • Resting blood pressure ≥160/100 mmHg
  • Malignancy, or severe renal or hepatic disease
  • Participants were free of any lipid-lowering therapies and postmenopausal hormone replacement therapy at least the 6 month period prior to enrollment
  • History of inflammatory condition or those taking medications that might affect inflammatory status within 6 months

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01099865

Layout table for location information
Korea, Republic of
Korea University Guro Hospital Dept. of Endocrinology
Seoul, Korea, Republic of
Sponsors and Collaborators
Korea University
Layout table for additonal information
Responsible Party: Korea Unoiversity Guro Hospital, IRB
ClinicalTrials.gov Identifier: NCT01099865    
Other Study ID Numbers: PET(DM)
First Posted: April 8, 2010    Key Record Dates
Last Update Posted: April 8, 2010
Last Verified: April 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases